Recent developments highlight Shattuck Labs' advancement of SL-325 into Phase 2b trials for Crohn's Disease and hidradenitis suppurativa, alongside reporting Q3 2026 financial results showing continued net losses and strong liquidity.

• Shattuck Labs reported third quarter 2026 financial results and initiated a Phase 2b trial of SL-325 [N1].
• The company advanced SL-325 into a Phase 2 trial for hidradenitis suppurativa [N3].
• Shattuck Labs incurred higher losses in Q2 2026 but continues clinical development of SL-325, planning Phase 2b Crohn's Disease trial in Q3 2026 [N5].
• The company was highlighted among top biotech gainers with plans to begin Crohn's Disease trial in Q3 2026 [N6].
• Shattuck Labs posted a narrower fiscal year 2025 loss and advanced its DR3 antibody pipeline [N7].
• Q4 loss dropped compared to prior periods, reflecting operational progress [N8].

Shattuck Labs' lead candidate SL-325 targets a clinically validated pathway with potential advantages over existing therapies due to its durable receptor binding and reduced immunogenicity. Advancement through Phase 1 and initiation of Phase 2 trials in Crohn's Disease and hidradenitis suppurativa demonstrate clinical progress. The company's strong liquidity supports ongoing development, and its pipeline of bispecific antibodies may expand therapeutic opportunities. Positive analyst coverage reflects recognition of the company's scientific and clinical potential.

Shattuck Labs operates in a high-risk clinical-stage biotech environment with no approved products and ongoing losses. Clinical trials carry inherent risks including safety, efficacy, and regulatory challenges. The company’s financial losses and reliance on capital markets for funding create execution risks. Immunogenicity and competitive landscape uncertainties remain, and bispecific antibody development may face technical and clinical hurdles. Market adoption depends on demonstrating clear clinical benefits over existing therapies.

Shattuck Labs' moat derives from its proprietary engineering of SL-325, a DR3 blocking antibody with high affinity and a unique epitope that avoids immune complex formation and receptor-mediated endocytosis, potentially offering superior efficacy and immunogenicity profiles compared to TL1A blocking antibodies. The company's focus on DR3, a receptor with stable expression in inflammatory diseases, and its development of bispecific antibodies targeting DR3 and other immune pathways, provide differentiation. Its intellectual property portfolio and clinical progress further support competitive positioning in the inflammatory disease therapeutic space.

• Clinical Development Risk: SL-325 and other pipeline candidates are in early clinical stages with inherent risks of failure due to safety, efficacy, or regulatory issues.
• Financial Risk: The company reported net losses and depends on sufficient liquidity and capital raising to fund ongoing operations and clinical trials.
• Immunogenicity Risk: Although SL-325 is engineered to reduce immunogenicity, unexpected immune responses could impact safety and efficacy.
• Competitive Risk: Other companies developing therapies targeting the DR3/TL1A pathway or alternative inflammatory disease treatments may limit market opportunities.

• Shattuck Labs, Inc. is a clinical-stage biotechnology company developing monoclonal and bispecific Death Receptor 3 (DR3) blocking antibodies for inflammatory and immune-mediated diseases [S1].
• The lead product candidate is SL-325, a high-affinity monoclonal antibody targeting DR3 to block the DR3/TL1A pathway, designed to achieve more complete and durable blockade than TL1A blocking antibodies [S1].
• SL-325 is engineered to avoid immune complex formation and has a potentially superior immunogenicity profile compared to TL1A blocking antibodies, which have high anti-drug antibody (ADA) formation rates [S1].
• SL-325 binds DR3 with very high affinity (1.3 picomolar), does not cause receptor-mediated endocytosis, and lacks Fc gamma receptor binding to reduce cytotoxicity risks [S1].
• SL-325 is in a Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial in healthy volunteers, with enrollment expected to complete in Q2 2026 [S1].
• A randomized, placebo-controlled Phase 2 clinical trial of SL-325 in Crohn's Disease patients was planned to initiate in Q3 2026 [S1].
• SL-325 is also being advanced into Phase 2b trials for Crohn's Disease and hidradenitis suppurativa as of late 2026 [N1][N3][N5].
• The company is developing SL-425, a half-life extended version of SL-325, currently in IND-enabling chronic toxicity studies [S1].
• Shattuck Labs is developing multiple preclinical DR3-based bispecific antibodies targeting DR3 and other immune targets, with disclosures planned in H1 2026 [S1].
• The DR3/TL1A pathway is clinically validated in inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's Disease, with TL1A blocking antibodies showing clinical remission rates of 23-28% in Phase 2 trials [S1].
• Shattuck Labs believes targeting DR3 may provide greater efficacy and durability than targeting TL1A due to differences in expression patterns and immunogenicity [S1].
• The company reported a net loss of $25.2 million for the quarter ended September 30, 2026, with basic and diluted EPS of -$0.14 per share [S2].
• As of September 30, 2026, Shattuck Labs held $61.8 million in cash and equivalents and had a current ratio of 15.8, indicating strong liquidity [S2].
• The company’s current assets were $201.6 million and current liabilities were $12.8 million as of September 30, 2026 [S2].
• SL-325’s Phase 1 trial evaluates safety, tolerability, pharmacokinetics, and immunogenicity to establish dosing for Phase 2 [S1].
• Recent news reports confirm initiation of Phase 2b trial of SL-325 and advancement into Phase 2 hidradenitis suppurativa trial [N1][N3].
• Shattuck Labs has incurred higher losses in Q2 2026 but continues advancing clinical programs [N5].
• The company has received analyst coverage with overweight and outperform recommendations from Cantor Fitzgerald, Piper Sandler, and Leerink Partners [N7][N8].